Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Crizotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 11/20 | 1.00 |
| ▸ | ALK known ✓ | Q9UM73 | 7/20 | 1.00 |
| ▸ | ROS1 known ✓ | P08922 | 2/20 | 1.00 |
| ▸ | MST1R known ✓ | Q04912 | 2/20 | 1.00 |
| ▸ | NPM1 known ✓ | P06748 | 1/20 | 1.00 |
| ▸ | EML4 known ✓ | Q9HC35 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 7/20 | 1.00 |
| ▸ | MAP4K3 | Q8IVH8 | 7/20 | 1.00 |
| ▸ | JAK3 | P52333 | 4/20 | 1.00 |
| ▸ | JAK1 | P23458 | 3/20 | 1.00 |
| ▸ | TYK2 | P29597 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 2/20 | 1.00 |
| ▸ | INSR | P06213 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crizotinib SCHEMBL93829 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL14811801 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29622387 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29831970 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL28844303 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL28844302 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29351506 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL30129754 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29831273 | 0.99 | MET (0.98) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL1827232 | 0.95 | MET (0.91) | METALKJAK2MAP4K3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241964-A1 | SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2025-07-31 | — | — | US | claimed |
| CN-115611861-A | Preparation method of crizotinib | 江苏万邦生化医药集团有限责任公司 | 2023-01-17 | — | — | CN | claimed |
| CN-111349082-A | Purification method of crizotinib | 江苏万邦生化医药集团有限责任公司 | 2020-06-30 | — | — | CN | claimed |
| CN-106632260-B | A kind of preparation method of small molecule kinase inhibitors | 上海天慈生物谷生物工程有限公司 | 2019-04-26 | — | — | CN | claimed |
| CN-106632263-B | A kind of synthetic method of (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine | 河南应用技术职业学院 | 2019-02-22 | — | — | CN | claimed |
| CN-109312406-A | It predicts in patients with lung cancer to the novel mutation in the anaplastic lymphoma kinase of the response of ALK inhibitor therapy | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | claimed |
| CN-108811499-A | Specific conjugation of cell binding molecules | 苏州美康加生物科技有限公司 | 2018-11-13 | — | — | CN | claimed |
| CN-108449940-A | Conjugated bridge linkers to cell binding molecules | 苏州美康加生物科技有限公司 | 2018-08-24 | — | — | CN | claimed |
| CN-108366992-A | Proteolysis targets chimera compound and its methods for making and using same | 耶鲁大学 | 2018-08-03 | — | — | CN | claimed |
| CN-108368075-A | Modified cytotoxins and therapeutic uses thereof | 加利福尼亚大学董事会 | 2018-08-03 | — | — | CN | claimed |
| CN-102898449-A | Method for synthesizing Crizotinib intermediate | UNIV TONGJI | 2013-01-30 | — | — | CN | claimed |
| US-8217057-B2 | Polymorphs of a c-MET/HGFR inhibitor | PFIZER INC. (US) | 2012-07-10 | — | — | US | claimed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| WO-2011067189-A2 | CMET INHIBITORS FOR TREATING ENDOMETRIOSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-09 | — | — | WO | claimed |
| EP-1959955-B1 | METHOD OF TREATING ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2010-11-17 | — | — | EP | claimed |
| US-7825137-B2 | Method of treating abnormal cell growth | PFIZER INC. (US) | 2010-11-02 | — | — | US | claimed |
| US-20080300273-A1 | administering to mammal a therapeutically effective amount of (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof, wherein the abnormal cell growth is a cancer mediated by an anaplastic lymphoma kinase | PFIZER INC. | 2008-12-04 | — | — | US | claimed |
| US-20080293769-A1 | Polymorphs of a C-Met/Hgfr Inhibitor | PFIZER INC. | 2008-11-27 | — | — | US | claimed |
| EP-1963302-A2 | POLYMORPHS OF A C-MET/HGFR INHIBITOR | Pfizer Products Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007066185-A2 | POLYMORPHS OF A C-MET/HGFR INHIBITOR | PFIZER PRODUCTS INC. (US) | 2007-06-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300273-A1 | administering to mammal a therapeutically effective amount of (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof, wherein the abnormal cell growth is a cancer mediated by an anaplastic lymphoma kinase | MET, HGF, HGFAC | MET 1/4885ALK 7/4885ROS1 53/4885 |
| US-20080293769-A1 | Polymorphs of a C-Met/Hgfr Inhibitor | MET, HGF, HGFAC | MET 1/4885ALK 90/4885ROS1 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.